Niger vs Palestine, State of: Prevalence rate of hypertension in men aged 30-79
Niger
40.4
in 2019
Palestine, State of
40.7
in 2019
Niger rank
66th
Palestine, State of rank
64th
Prevalence rate of hypertension in men aged 30-79 over time
- Niger
- Palestine, State of
How they compare
Palestine, State of currently reports 40.7 against 40.4 in Niger, a difference of 0.3.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Niger ahead.
Niger ranks 66th and Palestine, State of ranks 64th of 195 countries.
Niger has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Niger | Palestine, State of | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 41.83 | 38.38 | 3.45 | Niger |
| 2000s | 43.91 | 40.24 | 3.67 | Niger |
| 2010s | 42.27 | 40.67 | 1.6 | Niger |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Niger or Palestine, State of?
- Palestine, State of, at 40.7 against 40.4 in Niger as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Niger and Palestine, State of?
- 0.3, with Palestine, State of ahead.
- How many years of comparable data are there for Niger and Palestine, State of?
- 30 years are reported by both, from 1990 to 2019.
- How do Niger and Palestine, State of rank globally for prevalence rate of hypertension in men aged 30-79?
- Niger ranks 66th and Palestine, State of ranks 64th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.